AcelRx reclassifies DSUVIA as discontinued in FY2022 10-K after March 2023 asset sale to Alora

TALPHERA, INC.

On March 12, 2023, AcelRx sold DSUVIA/DZUVEO assets to Vertical Pharmaceuticals (Alora) and classified the business as discontinued from Q1 2023.
2022 Form 10-K MD&A and financial statements restated to show DSUVIA as discontinued operations for all periods presented.
Continuing operations exclude DSUVIA; remaining business includes Zalviso, other pipeline, and collaboration revenue.
Restatement aligns with discontinued operations presentation in Q1 2023 10-Q; no other changes to 2022 10-K.
Cash, equivalents, and investments totaled $17.7M at December 31, 2022 (per restated balance sheet).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.